Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

James Fisher reports solid half-year amid strategic turnaround

(Sharecast News) - James Fisher and Sons reported a solid first-half performance on Tuesday, in line with expectations, as it continued to make strategic progress in its turnaround. Despite growing macroeconomic uncertainties, the London-listed company said conditions in key end markets remained largely supportive, contributing to a robust trading performance.

For the six months ended 30 June, James Fisher said it expected underlying operating profit to be around £11m - a 14% increase driven by margin improvement from self-help initiatives and enhanced supply chain efficiency.

Revenue was set to be in line with the first half of 2024, after adjusting for the impact of disposals and business closures.

The firm's net debt-to-EBITDA ratio was projected to be around 1.7x, slightly above the target range of 1.0x to 1.5x, due to front-loaded capital investments aimed at supporting future growth.

The company said it continued to invest in new technology and product development, including the next generation of multi-role rebreathers, submarine capabilities, and tactical diving vehicles.

Those initiatives formed part of a broader effort to support long-term growth, with the energy and defence divisions being key focus areas.

In particular, James Fisher said it had targeted £19m in investments across its seven key sub-segments within energy and defence, including the replacement of its tankships fleet.

"I am pleased to report another period of solid trading and continued strategic progress through the James Fisher turnaround," said Jean Vernet, chief executive officer.

"Market conditions remain largely supportive, and we are focused on delivering on the next chapter of our business turnaround, positioning the Group for growth."

The board said the energy division performed well, particularly within well services, and made significant strides in decommissioning, which turned around prior year losses.

However, inspection, repair and maintenance (IRM) remained an area for improvement, with further progress expected in the second half of the year.

The board said the major port infrastructure project in Mozambique was successfully completed in the half-year.

In the defence division, the outlook was supported by increased global defence investment.

The business said it made important steps forward in growing strategic markets, including north east Asia and the US.

Meanwhile, maritime transport saw strong performance in tankships, driven by high utilisation and contracted rates, although Fendercare was impacted by the lack of LNG ship-to-ship activities.

James Fisher said it was continuing to focus on its strategic goals of achieving an underlying operating profit target of 10% and a return on capital employed target of 15%, with progress expected to be driven by self-help initiatives, improved business unit performance, supply chain integration, and a recovery in the defence division.

Trading in July had been in line with expectations, and the board said it remained confident in delivering further progress for the full year.

James Fisher said it would announce its interim results for the six months ended 30 June on 9 September.

At 1221 BST, shares in James Fisher and Sons were up 6.02% at 370p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.